×

Stocks GlaxoSmithKline PLC

  • 080514_whats_buffett_buying.jpg

    Even though Warren Buffett always says he likes stocks more when they're cheaper, he didn't do a lot of buying as Wall Street's major indexes fell to their bear-market lows (so far) in early March.  Berkshire Hathaway's first quarter stock portfolio snapshot shows no blockbuster buys. A few stakes did, however, get bigger during the first three months on the year.

  • Riders on the subway in Mexico City

    The World Health Organisation warned on Friday against a false sense of security from waning and apparently mild outbreaks of H1N1 flu, saying the worst may not be over.

  • GlaxoSmithKline

    The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.

  • A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.

  • Pharmacist wearing face mask

    Mexico has lowered its estimated death toll from new influenza strain referred to as swine flu to 101 from as many as 176. Italy reported its first case of the H1N1 virus.

  • Investors can benefit from certain health care companies that will be boosted by the stimulus package, said Les Funtleyder, health care strategist of Miller Tabak.

  • yoshikami_michael_100_2011.jpg

    Investors have a new variable that could potentially impact investment outcomes -- the flu. Your portfolio strategy will be impacted depending on how serious the spread of swine flu is and how dramatic the resulting panic turns out to be.

  • flu_outbreak3.jpg

    Here we go again. When I was relatively new on this beat I was thrown into covering the bird flu scare. At the time, many experts said it wasn't a question of if, but when it would come to the U.S. I'm still waiting. And I hope we're all waiting forever.

  • The futures are down again this morning with uncertainty of the impact that the swine flu will ultimately have.  So far, nearly 150 people have died in Mexico from the disease as it continues to spread around the world.  Here are some of the stocks that moved most as the story has developed.

  • graphic_word_ofthe_street.jpg

    Concerns that the recent outbreak of swine flu could reach pandemic proportions dragged down the Dow and S&P Monday with investors hammering airlines, hotels and more.

  • Stocks bounced back from a swine flu-induced drop Monday as traders scooped up shares of drug makers and pharmacies.

  • flu_outbreak2.jpg

    The threat of a widespread swine flu outbreak weighed on the markets Monday, and for good reason: Even if the virus is contained, it's still likely to put a crimp on spending for a wide array of goods.

  • graphic_fast_money.jpg

    Concerns that the swine flu could reach pandemic proportions sent money moving. Who wins and who loses?

  • Swine Flu: global pandemic or paranoia? President Obama said the health emergency declaration was merely a prudent measure. But many pharmaceutical stocks were sharply higher Monday in reaction to flu outbreaks — and the gains seemed to ripple through the sector.

  • As author of World Event Trading, I did an entire section on infectious diseases from the 1918 Spanish Flu to Bird Flu. The recent outbreak of Swine Flu is generating headlines and concerns globally......Critical point: fear of the disease is the biggest driver of behavior and societal changes due to the outbreak.

  • Financials continue to lead the weakness today on the heels of Bank of America’s earnings report. In late-morning trading, B of A and Citigroup are now down 15 percent each, while many other regional banks are 11 to 15 percent lower.

  • webxtra_thumb.jpg

    In this Web Extra, Pete Najarian talks Pharma takeovers. What's on his radar?

  • Pills

    An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.

  • Breakthrough diabetes treatments may be on the horizon. What companies stand to win?

  • A number of takeover rumors have been making the rounds, an encouraging sign that capitalistic optimism is returning to the markets.